

Company Name:	Maclin Sourcing Solutions Ltd
---------------	-------------------------------

Contact Name: Robert Lindfield

Contact Email: robert@maclingroup.co.uk

Purchase Order No: DRD20201123

Report Date: 12/03/2021

Melbec Ref Number: 22744

Name of Test Product: Prosan Hard Surface Anti-Viral Sanitising Wipes

Batch Number: n/a



Sample Details:

Manufacture / Supplier: Maclin Sourcing Solutions Ltd

Product storage conditions:..... Ambient and out of direct sunlight

Product appearance: Fluid extracted from wipes

Active substance and concentration: Didecyl Dimethylammonium Chloride (DDAC)

Diluent used to dilute product:...... Sterile Deionised Water

Product neutralisation procedure: MicroSpin S 400 HR columns and Large volume plating

Product appearance: Fluid extracted from a wipe

Incubation temperature: 37 °C \pm 1°C CO₂

The test product was in satisfactory condition for testing when received.

Date product received: 27/11/20 Test Date: 25/02/21

Experimental Conditions:

Interfering substance: Bovine Albumin (dirty 3.0g/l) plus 3.0ml/l erythrocytes

Test temperature: 20 +/- 1 °C Contact time: 5 minutes

Test organisms: Vaccinia virus VR-1508 (Modified Vaccinia Ankara)

Cell line identification: BHK-21 cells

Cell culture media: Dulbeco's minimum essential medium + 10.0% v/v foetal bovine serum

Requirements of the Standard:

The test product shall demonstrate at least a 4 decimal logarithm (lg) reduction when tested in accordance with this standard under simulated clean or dirty conditions.



_	
Concl	lusion:
COLIC	usioii.

For the product Vinco-SanWipe, [Batch code: n/a] the log reduction requirements as specified in BS EN 14476:2013+A2:2019 (4 lg within the relevant contact time) were met in dirty conditions with a contact time of 5 minutes.

Testing carried out by:

Name: Dr Nafisa Huq Position: Head of Virology Report authorised by:

Name: Dawn Mellors

Position: Technical Director

Date: 12/03/2021

All samples are tested as received and the condition on receipt is deemed to be satisfactory for testing unless client is informed otherwise. If an unsatisfactory sample is received and tested on instruction from the client comments are included on the report detailing this information. Results given for this may be invalid. Results detailed above relate only to the samples tested. Sample description and batch references stated are as provided by the customer. This test report shall not be reproduced except in full without the approval of Melbec Microbiology Ltd.



Method

Test procedure

To determine the virucidal activity of the product, test virus is exposed to product dilutions for the required contact time and subsequently, the product is neutralised. The solution is then serially diluted and titrated on cell monolayers. The surviving virus tissue culture infective dose ($TCID_{50}$) is determined by the appearance of cytopathic effect (CPE) on the cells and is calculated using the Spearman-Kärber calculation.

Several controls are run alongside each test to validate the assay.

Titration of Virus control: The titration of the virus test suspension is determined at the start of the test and at the end of the test to determine its infectivity.

Reference for Virus Inactivation control: Formaldehyde is used instead of the test product, at 2 time points to demonstrate that the virus remains resistant to biocidal action at known concentrations.

Efficiency of Suppression: The test product is neutralised during the test, prior to the addition of test virus. Recovery of the test virus at it's original titre demonstrates effective product neutralisation.

Interference control: Cell are incubated with the test product for 1 hour and subsequently the test virus is added. Recovery of the test virus at it's original titre demonstrates that the presence of the product does prevent infection of the cells by the test virus, and thus does not interfere with quantification of virucidal activity.

Cytotoxicity: Both the product and formaldehyde are incubated with cells, without the addition of test virus, to determine if any morphological changes occur that may mirror CPE normally caused by virus. This ensures any CPE seen is a result of residual virus and not the product.



Vaccinia virus VR-1508 (Modified Vaccinia Ankara)

Test Results					
Contact time	5 minutes	Raw data	log TCID₅₀/ml	Log reduction	
Product	t (RTU)	000000	4.50	4.25	
Product	t (50%)	066400	6.17	2.58	
Product (10%)		066660	7.50	1.25	
Virus Test Suspension	Start Finish	0666666 0666666	8.75		

Inactivation control (0.7% Formaldehyde)				
Contact time	Raw data	log TCID ₅₀ /ml	Log reduction	
5 min	066310	6.17	2.58	

Formaldehyde cytotoxicity			
Raw data 000000			
Level of cytotoxicity	2.50		

Product neutralisation				
Raw data	log TCID₅₀/ml	Log reduction		
0066666	8.83	-0.08		
Product cyto	otoxicity			
Product cyto	Level of cytotoxicity			

Product interference				
	Raw data	log TCID ₅₀ /ml	Log reduction	
PBS	0666666	8.83	-0.08	
Test product	0666666	8.50		
Difference		0.33		



Verification of the methodology

Result Summary	Log of TCID50	Average	Log Reduction	Criteria	met/not met	
Titration of Virus Control (Start)	8.83	8.75	0.75			
Titration of Virus Control (End)	8.67					
Product (RTU)	4.50		4.25	Log Reduction >= 4 Log	Met	
Product (50%)	6.17		2.58	Log Reduction >= 4 Log	N/A	
Product (10%)	7.50		1.25	Log Reduction <= 4 Log	Met	
Reference test for virus inactivation (15 mins)	5.83		2.92	2.0<=Log reduction=>4.0	Met	
Efficiency of Suppression	8.83		-0.08	<=0.5 log of Average	Met	
Inactivation Control (Product)	8.50		0.25	<=0.5 log of Average	Met	
Inactivation Control (PBS)	8.83		-0.08	<=0.5 log of Average	N/A	
Product Cytotoxicity	2.50				N/A	

- 1) The titre of the test suspension is at least 10^8 TCID50 /ml or is sufficiently high to at least enable a titre reduction of 4 lg to verify the method: detectable titre reduction shall be at least 4 lg.
- 2) The difference between the logarithmic titre of the virus control and the logarithmic titre of the test organism in the reference inactivation test should be between -2.0 and ≥ -4.0 after 15 min for the *Vaccinia virus*.
- 3) Cytotoxicity of the product test solution should not affect cell morphology and growth or susceptibility for the test organism in the dilutions of the test mixtures which are necessary to demonstrate a 4 lg reduction of the virus.
- 4) The product should not interfere with susceptibility of the cells to the test organism, the difference in the titre of the test suspension and the recovered titre of the interference control should be <1lg.
- 5) Control of efficiency for suppression of product activity (the difference to the test suspension shall be \leq 0,5 lg).
- 6) At least one concentration per test shall demonstrate a 4 lg or more reduction and at least one concentration shall demonstrate a lg reduction of less than 4.

End of Report